Xin Lang Cai Jing·2026-02-09 07:18Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a significant overseas revenue share [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and has both A and H share financing platforms [2]. - The main business segments include heparin raw materials, low molecular weight heparin products, and CDMO services, with revenue contributions of 63.06% from formulations, 18.59% from CDMO, and 16.05% from heparin products [7]. - As of September 30, 2025, the company reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The total market capitalization of Haiprui is 18.062 billion yuan, with a trading volume of 52.6162 million yuan on February 9 [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 27,000, with an average of 0 circulating shares per person [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan in the last three years [8]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited is the eighth largest circulating shareholder, holding 12.0093 million shares, an increase of 691,700 shares from the previous period [9].